Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 30;18(1):145.
doi: 10.1186/s12967-020-02308-w.

Ethnicity and survival in bladder cancer: a population-based study based on the SEER database

Wei Fang  1 , Zhi-Yan Yang  1 , Ting-Yu Chen  1 , Xian-Feng Shen  2 , Chao Zhang  3
Affiliations

Ethnicity and survival in bladder cancer: a population-based study based on the SEER database

Wei Fang et al. J Transl Med. .

Abstract

Background: Bladder cancer is the most common cancer in the urinary system and the fourth most common cancer in males. This study aimed to examine differences in the survival of bladder cancer patients of different ethnicities.

Method: We used the SEER database to obtain data pertaining to bladder cancer patients from 2010 to 2015. Univariate and multivariate Cox proportional hazards regression analyses were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between ethnicity and death. Kaplan-Meier survival and nomogram analyses were used to compare survival differences among patients with different ethnicities.

Results: Among 101,364 bladder cancer patients, 90,910 were white, 5893 were black, 337 were American Indian/Alaska Native (AIAN), and 4224 were Asian or Pacific Islander (API). Our multivariate analysis identified differences between different ethnicities. Compared to the API group, the AIAN (HR = 1.31, 95% CI = 1.09-1.57, P < 0.001), black (HR = 1.56, 95% CI = 1.46-1.67, P < 0.001), and white (HR = 1.18, 95% CI = 1.12-1.25, P < 0.001) groups showed lower survival probabilities. Based on data from all Kaplan-Meier survival curves, there was no significant difference in survival between the black and AIAN groups, but the survival of these two races was worse than that of the white and API groups. We also used a nomogram to estimate patient survival and validated its predictive value.

Conclusion: Our results suggest that ethnic differences exist in patients with bladder cancer, that the survival of black and AIAN bladder cancer patients is worse than that of other ethnicities and that the survival of API patients is the best. The significant prognostic factors of overall survival, which include age, sex, ethnicity, summary stage, American Joint Committee on Cancer stage, surgery type, and histologic type, should be applied to bladder cancer patient prognostication.

Keywords: Bladder cancer; Ethnic; Kaplan–Meier survival; SEER database; Survival rate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflicts of interest.

Figures

Fig. 1
Fig. 1
Kaplan–Meier survival curves for overall patients with bladder cancer in different conditions
Fig. 2
Fig. 2
Kaplan–Meier survival curves for different stage in different race of bladder cancer patients. Kaplan–Meier survival curves in different grade of stage 0a (a), stage 0is (b), stage I (c), stage II (d), stage III (e), and stage IV (f)
Fig. 3
Fig. 3
Kaplan–Meier survival for the difference of surgery and non-surgery in different race of bladder cancer patients
Fig. 4
Fig. 4
Nomogram of prediction for 3-year and 5-year overall survival of bladder cancer. Vertical line between each variable and points scale can be drawn to acquire points of each variable. Predicted survival rate was calculated according to the total points by drawing a vertical line from Total Points scale to overall survival scale
Fig. 5
Fig. 5
Calibration curves of the nomogram-predicted 3-year (a) and 5-year (b) overall survival
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. doi: 10.3322/caac.21254. - DOI - PubMed
    1. Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin. 2010;60:244–272. doi: 10.3322/caac.20077. - DOI - PubMed
    1. Siegel RL, Miller KD. Cancer statistics. 2019;2019(69):7–34. - PubMed
    1. Morrison AS, Proppe KH, Verhoek WG, Aoki K, Leck I, Ohno Y, et al. Histologic features of bladder cancer in Boston, USA, Manchester, UK, and Nagoya, Japan. Int J Cancer. 2010;30:701–705. doi: 10.1002/ijc.2910300605. - DOI - PubMed
    1. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239–249. doi: 10.1016/S0140-6736(09)60491-8. - DOI - PubMed